Global Peptide Cancer Vaccine Market Growth 2025-2031
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Peptide Cancer Vaccine market size is predicted to grow from US$ 766 million in 2025 to US$ 2349 million in 2031; it is expected to grow at a CAGR of 20.5% from 2025 to 2031.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
LP Information, Inc. (LPI) ' newest research report, the “Peptide Cancer Vaccine Industry Forecast” looks at past sales and reviews total world Peptide Cancer Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide Cancer Vaccine sales for 2025 through 2031. With Peptide Cancer Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Cancer Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Peptide Cancer Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide Cancer Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide Cancer Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Cancer Vaccine and breaks down the forecast by Pipeline, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Cancer Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Cancer Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Pipeline:
What is the 10-year outlook for the global Peptide Cancer Vaccine market?
What factors are driving Peptide Cancer Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peptide Cancer Vaccine market opportunities vary by end market size?
How does Peptide Cancer Vaccine break out by Pipeline, by Application?
The global Peptide Cancer Vaccine market size is predicted to grow from US$ 766 million in 2025 to US$ 2349 million in 2031; it is expected to grow at a CAGR of 20.5% from 2025 to 2031.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
LP Information, Inc. (LPI) ' newest research report, the “Peptide Cancer Vaccine Industry Forecast” looks at past sales and reviews total world Peptide Cancer Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide Cancer Vaccine sales for 2025 through 2031. With Peptide Cancer Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Cancer Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Peptide Cancer Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide Cancer Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide Cancer Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Cancer Vaccine and breaks down the forecast by Pipeline, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Cancer Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Cancer Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Pipeline:
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
What is the 10-year outlook for the global Peptide Cancer Vaccine market?
What factors are driving Peptide Cancer Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peptide Cancer Vaccine market opportunities vary by end market size?
How does Peptide Cancer Vaccine break out by Pipeline, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide Cancer Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Peptide Cancer Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Peptide Cancer Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Peptide Cancer Vaccine Segment by Pipeline
2.2.1 ITK-1
2.2.2 GRN-1201
2.2.3 TPIV200
2.2.4 TPIV110
2.2.5 UV1
2.2.6 Galinpepimut-S
2.2.7 TARP 27-35
2.2.8 HER-Vaxx
2.2.9 Vx-001
2.3 Peptide Cancer Vaccine Sales by Pipeline
2.3.1 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
2.3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Pipeline (2020-2025)
2.3.3 Global Peptide Cancer Vaccine Sale Price by Pipeline (2020-2025)
2.4 Peptide Cancer Vaccine Segment by Application
2.4.1 Breast Cancer
2.4.2 Lung Cancer
2.4.3 Melanoma
2.4.4 Prostate Cancer
2.4.5 Others
2.5 Peptide Cancer Vaccine Sales by Application
2.5.1 Global Peptide Cancer Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Peptide Cancer Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Peptide Cancer Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Peptide Cancer Vaccine Breakdown Data by Company
3.1.1 Global Peptide Cancer Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Peptide Cancer Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Peptide Cancer Vaccine Revenue by Company (2020-2025)
3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Peptide Cancer Vaccine Sale Price by Company
3.4 Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Cancer Vaccine Product Location Distribution
3.4.2 Players Peptide Cancer Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PEPTIDE CANCER VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Peptide Cancer Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Peptide Cancer Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Peptide Cancer Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Peptide Cancer Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Peptide Cancer Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Peptide Cancer Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Peptide Cancer Vaccine Sales Growth
4.4 APAC Peptide Cancer Vaccine Sales Growth
4.5 Europe Peptide Cancer Vaccine Sales Growth
4.6 Middle East & Africa Peptide Cancer Vaccine Sales Growth
5 AMERICAS
5.1 Americas Peptide Cancer Vaccine Sales by Country
5.1.1 Americas Peptide Cancer Vaccine Sales by Country (2020-2025)
5.1.2 Americas Peptide Cancer Vaccine Revenue by Country (2020-2025)
5.2 Americas Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
5.3 Americas Peptide Cancer Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Cancer Vaccine Sales by Region
6.1.1 APAC Peptide Cancer Vaccine Sales by Region (2020-2025)
6.1.2 APAC Peptide Cancer Vaccine Revenue by Region (2020-2025)
6.2 APAC Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
6.3 APAC Peptide Cancer Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Peptide Cancer Vaccine by Country
7.1.1 Europe Peptide Cancer Vaccine Sales by Country (2020-2025)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Country (2020-2025)
7.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
7.3 Europe Peptide Cancer Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide Cancer Vaccine by Country
8.1.1 Middle East & Africa Peptide Cancer Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
8.3 Middle East & Africa Peptide Cancer Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine
10.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
10.4 Industry Chain Structure of Peptide Cancer Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Cancer Vaccine Distributors
11.3 Peptide Cancer Vaccine Customer
12 WORLD FORECAST REVIEW FOR PEPTIDE CANCER VACCINE BY GEOGRAPHIC REGION
12.1 Global Peptide Cancer Vaccine Market Size Forecast by Region
12.1.1 Global Peptide Cancer Vaccine Forecast by Region (2026-2031)
12.1.2 Global Peptide Cancer Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Peptide Cancer Vaccine Forecast by Pipeline (2026-2031)
12.7 Global Peptide Cancer Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Boston Biomedical
13.1.1 Boston Biomedical Company Information
13.1.2 Boston Biomedical Peptide Cancer Vaccine Product Portfolios and Specifications
13.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Boston Biomedical Main Business Overview
13.1.5 Boston Biomedical Latest Developments
13.2 Ultimovacs
13.2.1 Ultimovacs Company Information
13.2.2 Ultimovacs Peptide Cancer Vaccine Product Portfolios and Specifications
13.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Ultimovacs Main Business Overview
13.2.5 Ultimovacs Latest Developments
13.3 BrightPath Biotherapeutics
13.3.1 BrightPath Biotherapeutics Company Information
13.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolios and Specifications
13.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 BrightPath Biotherapeutics Main Business Overview
13.3.5 BrightPath Biotherapeutics Latest Developments
13.4 TapImmune
13.4.1 TapImmune Company Information
13.4.2 TapImmune Peptide Cancer Vaccine Product Portfolios and Specifications
13.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 TapImmune Main Business Overview
13.4.5 TapImmune Latest Developments
13.5 Immatics
13.5.1 Immatics Company Information
13.5.2 Immatics Peptide Cancer Vaccine Product Portfolios and Specifications
13.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Immatics Main Business Overview
13.5.5 Immatics Latest Developments
13.6 Sellas
13.6.1 Sellas Company Information
13.6.2 Sellas Peptide Cancer Vaccine Product Portfolios and Specifications
13.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sellas Main Business Overview
13.6.5 Sellas Latest Developments
13.7 Imugene
13.7.1 Imugene Company Information
13.7.2 Imugene Peptide Cancer Vaccine Product Portfolios and Specifications
13.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Imugene Main Business Overview
13.7.5 Imugene Latest Developments
13.8 VAXON Biotech
13.8.1 VAXON Biotech Company Information
13.8.2 VAXON Biotech Peptide Cancer Vaccine Product Portfolios and Specifications
13.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 VAXON Biotech Main Business Overview
13.8.5 VAXON Biotech Latest Developments
13.9 Generex Biotechnology
13.9.1 Generex Biotechnology Company Information
13.9.2 Generex Biotechnology Peptide Cancer Vaccine Product Portfolios and Specifications
13.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Generex Biotechnology Main Business Overview
13.9.5 Generex Biotechnology Latest Developments
13.10 ISA Pharmaceuticals
13.10.1 ISA Pharmaceuticals Company Information
13.10.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolios and Specifications
13.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 ISA Pharmaceuticals Main Business Overview
13.10.5 ISA Pharmaceuticals Latest Developments
13.11 OncoTherapy Science
13.11.1 OncoTherapy Science Company Information
13.11.2 OncoTherapy Science Peptide Cancer Vaccine Product Portfolios and Specifications
13.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 OncoTherapy Science Main Business Overview
13.11.5 OncoTherapy Science Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Peptide Cancer Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Peptide Cancer Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of ITK-1
Table 4. Major Players of GRN-1201
Table 5. Major Players ofTPIV200
Table 6. Major Players ofTPIV110
Table 7. Major Players of UV1
Table 8. Major Players of Galinpepimut-S
Table 9. Major Players ofTARP 27-35
Table 10. Major Players of HER-Vaxx
Table 11. Major Players of Vx-001
Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 13. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Table 14. Global Peptide Cancer Vaccine Revenue by Pipeline (2020-2025) & ($ million)
Table 15. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2020-2025)
Table 16. Global Peptide Cancer Vaccine Sale Price by Pipeline (2020-2025) & (USD/Unit)
Table 17. Global Peptide Cancer Vaccine Sale by Application (2020-2025) & (K Units)
Table 18. Global Peptide Cancer Vaccine Sale Market Share by Application (2020-2025)
Table 19. Global Peptide Cancer Vaccine Revenue by Application (2020-2025) & ($ million)
Table 20. Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2025)
Table 21. Global Peptide Cancer Vaccine Sale Price by Application (2020-2025) & (USD/Unit)
Table 22. Global Peptide Cancer Vaccine Sales by Company (2020-2025) & (K Units)
Table 23. Global Peptide Cancer Vaccine Sales Market Share by Company (2020-2025)
Table 24. Global Peptide Cancer Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2025)
Table 26. Global Peptide Cancer Vaccine Sale Price by Company (2020-2025) & (USD/Unit)
Table 27. Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution and Sales Area
Table 28. Players Peptide Cancer Vaccine Products Offered
Table 29. Peptide Cancer Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 30. New Products and Potential Entrants
Table 31. Market M&A Activity & Strategy
Table 32. Global Peptide Cancer Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 33. Global Peptide Cancer Vaccine Sales Market Share Geographic Region (2020-2025)
Table 34. Global Peptide Cancer Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 36. Global Peptide Cancer Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 37. Global Peptide Cancer Vaccine Sales Market Share by Country/Region (2020-2025)
Table 38. Global Peptide Cancer Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 39. Global Peptide Cancer Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 40. Americas Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Units)
Table 41. Americas Peptide Cancer Vaccine Sales Market Share by Country (2020-2025)
Table 42. Americas Peptide Cancer Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 43. Americas Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 44. Americas Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 45. APAC Peptide Cancer Vaccine Sales by Region (2020-2025) & (K Units)
Table 46. APAC Peptide Cancer Vaccine Sales Market Share by Region (2020-2025)
Table 47. APAC Peptide Cancer Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 48. APAC Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 49. APAC Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 50. Europe Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Units)
Table 51. Europe Peptide Cancer Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 52. Europe Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 53. Europe Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 54. Middle East & Africa Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Units)
Table 55. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country (2020-2025)
Table 56. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 57. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Peptide Cancer Vaccine
Table 59. Key Market Challenges & Risks of Peptide Cancer Vaccine
Table 60. Key IndustryTrends of Peptide Cancer Vaccine
Table 61. Peptide Cancer Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Peptide Cancer Vaccine Distributors List
Table 64. Peptide Cancer Vaccine Customer List
Table 65. Global Peptide Cancer Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 66. Global Peptide Cancer Vaccine RevenueForecast by Region (2026-2031) & ($ millions)
Table 67. Americas Peptide Cancer Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 68. Americas Peptide Cancer Vaccine Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. APAC Peptide Cancer Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 70. APAC Peptide Cancer Vaccine Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 71. Europe Peptide Cancer Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 72. Europe Peptide Cancer Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 73. Middle East & Africa Peptide Cancer Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 74. Middle East & Africa Peptide Cancer Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 75. Global Peptide Cancer Vaccine SalesForecast by Pipeline (2026-2031) & (K Units)
Table 76. Global Peptide Cancer Vaccine RevenueForecast by Pipeline (2026-2031) & ($ millions)
Table 77. Global Peptide Cancer Vaccine SalesForecast by Application (2026-2031) & (K Units)
Table 78. Global Peptide Cancer Vaccine RevenueForecast by Application (2026-2031) & ($ millions)
Table 79. Boston Biomedical Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Boston Biomedical Peptide Cancer Vaccine Product Portfolios and Specifications
Table 81. Boston Biomedical Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Boston Biomedical Main Business
Table 83. Boston Biomedical Latest Developments
Table 84. Ultimovacs Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Ultimovacs Peptide Cancer Vaccine Product Portfolios and Specifications
Table 86. Ultimovacs Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. Ultimovacs Main Business
Table 88. Ultimovacs Latest Developments
Table 89. BrightPath Biotherapeutics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolios and Specifications
Table 91. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. BrightPath Biotherapeutics Main Business
Table 93. BrightPath Biotherapeutics Latest Developments
Table 94.TapImmune Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95.TapImmune Peptide Cancer Vaccine Product Portfolios and Specifications
Table 96.TapImmune Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97.TapImmune Main Business
Table 98.TapImmune Latest Developments
Table 99. Immatics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Immatics Peptide Cancer Vaccine Product Portfolios and Specifications
Table 101. Immatics Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Immatics Main Business
Table 103. Immatics Latest Developments
Table 104. Sellas Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Sellas Peptide Cancer Vaccine Product Portfolios and Specifications
Table 106. Sellas Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Sellas Main Business
Table 108. Sellas Latest Developments
Table 109. Imugene Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Imugene Peptide Cancer Vaccine Product Portfolios and Specifications
Table 111. Imugene Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Imugene Main Business
Table 113. Imugene Latest Developments
Table 114. VAXON Biotech Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. VAXON Biotech Peptide Cancer Vaccine Product Portfolios and Specifications
Table 116. VAXON Biotech Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. VAXON Biotech Main Business
Table 118. VAXON Biotech Latest Developments
Table 119. Generex Biotechnology Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Generex Biotechnology Peptide Cancer Vaccine Product Portfolios and Specifications
Table 121. Generex Biotechnology Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Generex Biotechnology Main Business
Table 123. Generex Biotechnology Latest Developments
Table 124. ISA Pharmaceuticals Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolios and Specifications
Table 126. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. ISA Pharmaceuticals Main Business
Table 128. ISA Pharmaceuticals Latest Developments
Table 129. OncoTherapy Science Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. OncoTherapy Science Peptide Cancer Vaccine Product Portfolios and Specifications
Table 131. OncoTherapy Science Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. OncoTherapy Science Main Business
Table 133. OncoTherapy Science Latest Developments
LIST OFFIGURES
Figure 1. Picture of Peptide Cancer Vaccine
Figure 2. Peptide Cancer Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Cancer Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Peptide Cancer Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Peptide Cancer Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Peptide Cancer Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Peptide Cancer Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of ITK-1
Figure 12. Product Picture of GRN-1201
Figure 13. Product Picture ofTPIV200
Figure 14. Product Picture ofTPIV110
Figure 15. Product Picture of UV1
Figure 16. Product Picture of Galinpepimut-S
Figure 17. Product Picture ofTARP 27-35
Figure 18. Product Picture of HER-Vaxx
Figure 19. Product Picture of Vx-001
Figure 20. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2025
Figure 21. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2020-2025)
Figure 22. Peptide Cancer Vaccine Consumed in Breast Cancer
Figure 23. Global Peptide Cancer Vaccine Market: Breast Cancer (2020-2025) & (K Units)
Figure 24. Peptide Cancer Vaccine Consumed in Lung Cancer
Figure 25. Global Peptide Cancer Vaccine Market: Lung Cancer (2020-2025) & (K Units)
Figure 26. Peptide Cancer Vaccine Consumed in Melanoma
Figure 27. Global Peptide Cancer Vaccine Market: Melanoma (2020-2025) & (K Units)
Figure 28. Peptide Cancer Vaccine Consumed in Prostate Cancer
Figure 29. Global Peptide Cancer Vaccine Market: Prostate Cancer (2020-2025) & (K Units)
Figure 30. Peptide Cancer Vaccine Consumed in Others
Figure 31. Global Peptide Cancer Vaccine Market: Others (2020-2025) & (K Units)
Figure 32. Global Peptide Cancer Vaccine Sale Market Share by Application (2024)
Figure 33. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2025
Figure 34. Peptide Cancer Vaccine Sales by Company in 2025 (K Units)
Figure 35. Global Peptide Cancer Vaccine Sales Market Share by Company in 2025
Figure 36. Peptide Cancer Vaccine Revenue by Company in 2025 ($ millions)
Figure 37. Global Peptide Cancer Vaccine Revenue Market Share by Company in 2025
Figure 38. Global Peptide Cancer Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 39. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 41. Americas Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 42. APAC Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 43. APAC Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 44. Europe Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 45. Europe Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 46. Middle East & Africa Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 47. Middle East & Africa Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 48. Americas Peptide Cancer Vaccine Sales Market Share by Country in 2025
Figure 49. Americas Peptide Cancer Vaccine Revenue Market Share by Country (2020-2025)
Figure 50. Americas Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 51. Americas Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 52. United States Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. Canada Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Mexico Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. Brazil Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. APAC Peptide Cancer Vaccine Sales Market Share by Region in 2025
Figure 57. APAC Peptide Cancer Vaccine Revenue Market Share by Region (2020-2025)
Figure 58. APAC Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 59. APAC Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 60. China Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Japan Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. South Korea Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Southeast Asia Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. India Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. Australia Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. ChinaTaiwan Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2025
Figure 68. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2020-2025)
Figure 69. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 70. Europe Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 71. Germany Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72.France Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. UK Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. Italy Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 75. Russia Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 76. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country (2020-2025)
Figure 77. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 78. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 79. Egypt Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 80. South Africa Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 81. Israel Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 82.Turkey Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 83. GCC Countries Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine in 2025
Figure 85. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 86. Industry Chain Structure of Peptide Cancer Vaccine
Figure 87. Channels of Distribution
Figure 88. Global Peptide Cancer Vaccine Sales MarketForecast by Region (2026-2031)
Figure 89. Global Peptide Cancer Vaccine Revenue Market ShareForecast by Region (2026-2031)
Figure 90. Global Peptide Cancer Vaccine Sales Market ShareForecast by Pipeline (2026-2031)
Figure 91. Global Peptide Cancer Vaccine Revenue Market ShareForecast by Pipeline (2026-2031)
Figure 92. Global Peptide Cancer Vaccine Sales Market ShareForecast by Application (2026-2031)
Figure 93. Global Peptide Cancer Vaccine Revenue Market ShareForecast by Application (2026-2031)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide Cancer Vaccine Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Peptide Cancer Vaccine by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Peptide Cancer Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Peptide Cancer Vaccine Segment by Pipeline
2.2.1 ITK-1
2.2.2 GRN-1201
2.2.3 TPIV200
2.2.4 TPIV110
2.2.5 UV1
2.2.6 Galinpepimut-S
2.2.7 TARP 27-35
2.2.8 HER-Vaxx
2.2.9 Vx-001
2.3 Peptide Cancer Vaccine Sales by Pipeline
2.3.1 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
2.3.2 Global Peptide Cancer Vaccine Revenue and Market Share by Pipeline (2020-2025)
2.3.3 Global Peptide Cancer Vaccine Sale Price by Pipeline (2020-2025)
2.4 Peptide Cancer Vaccine Segment by Application
2.4.1 Breast Cancer
2.4.2 Lung Cancer
2.4.3 Melanoma
2.4.4 Prostate Cancer
2.4.5 Others
2.5 Peptide Cancer Vaccine Sales by Application
2.5.1 Global Peptide Cancer Vaccine Sale Market Share by Application (2020-2025)
2.5.2 Global Peptide Cancer Vaccine Revenue and Market Share by Application (2020-2025)
2.5.3 Global Peptide Cancer Vaccine Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Peptide Cancer Vaccine Breakdown Data by Company
3.1.1 Global Peptide Cancer Vaccine Annual Sales by Company (2020-2025)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Peptide Cancer Vaccine Annual Revenue by Company (2020-2025)
3.2.1 Global Peptide Cancer Vaccine Revenue by Company (2020-2025)
3.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Peptide Cancer Vaccine Sale Price by Company
3.4 Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Cancer Vaccine Product Location Distribution
3.4.2 Players Peptide Cancer Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PEPTIDE CANCER VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Peptide Cancer Vaccine Market Size by Geographic Region (2020-2025)
4.1.1 Global Peptide Cancer Vaccine Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Peptide Cancer Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Peptide Cancer Vaccine Market Size by Country/Region (2020-2025)
4.2.1 Global Peptide Cancer Vaccine Annual Sales by Country/Region (2020-2025)
4.2.2 Global Peptide Cancer Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Peptide Cancer Vaccine Sales Growth
4.4 APAC Peptide Cancer Vaccine Sales Growth
4.5 Europe Peptide Cancer Vaccine Sales Growth
4.6 Middle East & Africa Peptide Cancer Vaccine Sales Growth
5 AMERICAS
5.1 Americas Peptide Cancer Vaccine Sales by Country
5.1.1 Americas Peptide Cancer Vaccine Sales by Country (2020-2025)
5.1.2 Americas Peptide Cancer Vaccine Revenue by Country (2020-2025)
5.2 Americas Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
5.3 Americas Peptide Cancer Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Cancer Vaccine Sales by Region
6.1.1 APAC Peptide Cancer Vaccine Sales by Region (2020-2025)
6.1.2 APAC Peptide Cancer Vaccine Revenue by Region (2020-2025)
6.2 APAC Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
6.3 APAC Peptide Cancer Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Peptide Cancer Vaccine by Country
7.1.1 Europe Peptide Cancer Vaccine Sales by Country (2020-2025)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Country (2020-2025)
7.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
7.3 Europe Peptide Cancer Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide Cancer Vaccine by Country
8.1.1 Middle East & Africa Peptide Cancer Vaccine Sales by Country (2020-2025)
8.1.2 Middle East & Africa Peptide Cancer Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2020-2025)
8.3 Middle East & Africa Peptide Cancer Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine
10.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
10.4 Industry Chain Structure of Peptide Cancer Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Cancer Vaccine Distributors
11.3 Peptide Cancer Vaccine Customer
12 WORLD FORECAST REVIEW FOR PEPTIDE CANCER VACCINE BY GEOGRAPHIC REGION
12.1 Global Peptide Cancer Vaccine Market Size Forecast by Region
12.1.1 Global Peptide Cancer Vaccine Forecast by Region (2026-2031)
12.1.2 Global Peptide Cancer Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Peptide Cancer Vaccine Forecast by Pipeline (2026-2031)
12.7 Global Peptide Cancer Vaccine Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Boston Biomedical
13.1.1 Boston Biomedical Company Information
13.1.2 Boston Biomedical Peptide Cancer Vaccine Product Portfolios and Specifications
13.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Boston Biomedical Main Business Overview
13.1.5 Boston Biomedical Latest Developments
13.2 Ultimovacs
13.2.1 Ultimovacs Company Information
13.2.2 Ultimovacs Peptide Cancer Vaccine Product Portfolios and Specifications
13.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Ultimovacs Main Business Overview
13.2.5 Ultimovacs Latest Developments
13.3 BrightPath Biotherapeutics
13.3.1 BrightPath Biotherapeutics Company Information
13.3.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolios and Specifications
13.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 BrightPath Biotherapeutics Main Business Overview
13.3.5 BrightPath Biotherapeutics Latest Developments
13.4 TapImmune
13.4.1 TapImmune Company Information
13.4.2 TapImmune Peptide Cancer Vaccine Product Portfolios and Specifications
13.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 TapImmune Main Business Overview
13.4.5 TapImmune Latest Developments
13.5 Immatics
13.5.1 Immatics Company Information
13.5.2 Immatics Peptide Cancer Vaccine Product Portfolios and Specifications
13.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Immatics Main Business Overview
13.5.5 Immatics Latest Developments
13.6 Sellas
13.6.1 Sellas Company Information
13.6.2 Sellas Peptide Cancer Vaccine Product Portfolios and Specifications
13.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Sellas Main Business Overview
13.6.5 Sellas Latest Developments
13.7 Imugene
13.7.1 Imugene Company Information
13.7.2 Imugene Peptide Cancer Vaccine Product Portfolios and Specifications
13.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Imugene Main Business Overview
13.7.5 Imugene Latest Developments
13.8 VAXON Biotech
13.8.1 VAXON Biotech Company Information
13.8.2 VAXON Biotech Peptide Cancer Vaccine Product Portfolios and Specifications
13.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 VAXON Biotech Main Business Overview
13.8.5 VAXON Biotech Latest Developments
13.9 Generex Biotechnology
13.9.1 Generex Biotechnology Company Information
13.9.2 Generex Biotechnology Peptide Cancer Vaccine Product Portfolios and Specifications
13.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Generex Biotechnology Main Business Overview
13.9.5 Generex Biotechnology Latest Developments
13.10 ISA Pharmaceuticals
13.10.1 ISA Pharmaceuticals Company Information
13.10.2 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolios and Specifications
13.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 ISA Pharmaceuticals Main Business Overview
13.10.5 ISA Pharmaceuticals Latest Developments
13.11 OncoTherapy Science
13.11.1 OncoTherapy Science Company Information
13.11.2 OncoTherapy Science Peptide Cancer Vaccine Product Portfolios and Specifications
13.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 OncoTherapy Science Main Business Overview
13.11.5 OncoTherapy Science Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Peptide Cancer Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Peptide Cancer Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of ITK-1
Table 4. Major Players of GRN-1201
Table 5. Major Players ofTPIV200
Table 6. Major Players ofTPIV110
Table 7. Major Players of UV1
Table 8. Major Players of Galinpepimut-S
Table 9. Major Players ofTARP 27-35
Table 10. Major Players of HER-Vaxx
Table 11. Major Players of Vx-001
Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 13. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Table 14. Global Peptide Cancer Vaccine Revenue by Pipeline (2020-2025) & ($ million)
Table 15. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2020-2025)
Table 16. Global Peptide Cancer Vaccine Sale Price by Pipeline (2020-2025) & (USD/Unit)
Table 17. Global Peptide Cancer Vaccine Sale by Application (2020-2025) & (K Units)
Table 18. Global Peptide Cancer Vaccine Sale Market Share by Application (2020-2025)
Table 19. Global Peptide Cancer Vaccine Revenue by Application (2020-2025) & ($ million)
Table 20. Global Peptide Cancer Vaccine Revenue Market Share by Application (2020-2025)
Table 21. Global Peptide Cancer Vaccine Sale Price by Application (2020-2025) & (USD/Unit)
Table 22. Global Peptide Cancer Vaccine Sales by Company (2020-2025) & (K Units)
Table 23. Global Peptide Cancer Vaccine Sales Market Share by Company (2020-2025)
Table 24. Global Peptide Cancer Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2025)
Table 26. Global Peptide Cancer Vaccine Sale Price by Company (2020-2025) & (USD/Unit)
Table 27. Key Manufacturers Peptide Cancer Vaccine Producing Area Distribution and Sales Area
Table 28. Players Peptide Cancer Vaccine Products Offered
Table 29. Peptide Cancer Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 30. New Products and Potential Entrants
Table 31. Market M&A Activity & Strategy
Table 32. Global Peptide Cancer Vaccine Sales by Geographic Region (2020-2025) & (K Units)
Table 33. Global Peptide Cancer Vaccine Sales Market Share Geographic Region (2020-2025)
Table 34. Global Peptide Cancer Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 35. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 36. Global Peptide Cancer Vaccine Sales by Country/Region (2020-2025) & (K Units)
Table 37. Global Peptide Cancer Vaccine Sales Market Share by Country/Region (2020-2025)
Table 38. Global Peptide Cancer Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 39. Global Peptide Cancer Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 40. Americas Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Units)
Table 41. Americas Peptide Cancer Vaccine Sales Market Share by Country (2020-2025)
Table 42. Americas Peptide Cancer Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 43. Americas Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 44. Americas Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 45. APAC Peptide Cancer Vaccine Sales by Region (2020-2025) & (K Units)
Table 46. APAC Peptide Cancer Vaccine Sales Market Share by Region (2020-2025)
Table 47. APAC Peptide Cancer Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 48. APAC Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 49. APAC Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 50. Europe Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Units)
Table 51. Europe Peptide Cancer Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 52. Europe Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 53. Europe Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 54. Middle East & Africa Peptide Cancer Vaccine Sales by Country (2020-2025) & (K Units)
Table 55. Middle East & Africa Peptide Cancer Vaccine Revenue Market Share by Country (2020-2025)
Table 56. Middle East & Africa Peptide Cancer Vaccine Sales by Pipeline (2020-2025) & (K Units)
Table 57. Middle East & Africa Peptide Cancer Vaccine Sales by Application (2020-2025) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Peptide Cancer Vaccine
Table 59. Key Market Challenges & Risks of Peptide Cancer Vaccine
Table 60. Key IndustryTrends of Peptide Cancer Vaccine
Table 61. Peptide Cancer Vaccine Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Peptide Cancer Vaccine Distributors List
Table 64. Peptide Cancer Vaccine Customer List
Table 65. Global Peptide Cancer Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 66. Global Peptide Cancer Vaccine RevenueForecast by Region (2026-2031) & ($ millions)
Table 67. Americas Peptide Cancer Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 68. Americas Peptide Cancer Vaccine Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. APAC Peptide Cancer Vaccine SalesForecast by Region (2026-2031) & (K Units)
Table 70. APAC Peptide Cancer Vaccine Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 71. Europe Peptide Cancer Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 72. Europe Peptide Cancer Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 73. Middle East & Africa Peptide Cancer Vaccine SalesForecast by Country (2026-2031) & (K Units)
Table 74. Middle East & Africa Peptide Cancer Vaccine RevenueForecast by Country (2026-2031) & ($ millions)
Table 75. Global Peptide Cancer Vaccine SalesForecast by Pipeline (2026-2031) & (K Units)
Table 76. Global Peptide Cancer Vaccine RevenueForecast by Pipeline (2026-2031) & ($ millions)
Table 77. Global Peptide Cancer Vaccine SalesForecast by Application (2026-2031) & (K Units)
Table 78. Global Peptide Cancer Vaccine RevenueForecast by Application (2026-2031) & ($ millions)
Table 79. Boston Biomedical Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. Boston Biomedical Peptide Cancer Vaccine Product Portfolios and Specifications
Table 81. Boston Biomedical Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 82. Boston Biomedical Main Business
Table 83. Boston Biomedical Latest Developments
Table 84. Ultimovacs Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Ultimovacs Peptide Cancer Vaccine Product Portfolios and Specifications
Table 86. Ultimovacs Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. Ultimovacs Main Business
Table 88. Ultimovacs Latest Developments
Table 89. BrightPath Biotherapeutics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolios and Specifications
Table 91. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 92. BrightPath Biotherapeutics Main Business
Table 93. BrightPath Biotherapeutics Latest Developments
Table 94.TapImmune Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95.TapImmune Peptide Cancer Vaccine Product Portfolios and Specifications
Table 96.TapImmune Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 97.TapImmune Main Business
Table 98.TapImmune Latest Developments
Table 99. Immatics Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Immatics Peptide Cancer Vaccine Product Portfolios and Specifications
Table 101. Immatics Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 102. Immatics Main Business
Table 103. Immatics Latest Developments
Table 104. Sellas Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Sellas Peptide Cancer Vaccine Product Portfolios and Specifications
Table 106. Sellas Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 107. Sellas Main Business
Table 108. Sellas Latest Developments
Table 109. Imugene Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Imugene Peptide Cancer Vaccine Product Portfolios and Specifications
Table 111. Imugene Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 112. Imugene Main Business
Table 113. Imugene Latest Developments
Table 114. VAXON Biotech Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. VAXON Biotech Peptide Cancer Vaccine Product Portfolios and Specifications
Table 116. VAXON Biotech Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 117. VAXON Biotech Main Business
Table 118. VAXON Biotech Latest Developments
Table 119. Generex Biotechnology Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Generex Biotechnology Peptide Cancer Vaccine Product Portfolios and Specifications
Table 121. Generex Biotechnology Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Generex Biotechnology Main Business
Table 123. Generex Biotechnology Latest Developments
Table 124. ISA Pharmaceuticals Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolios and Specifications
Table 126. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. ISA Pharmaceuticals Main Business
Table 128. ISA Pharmaceuticals Latest Developments
Table 129. OncoTherapy Science Basic Information, Peptide Cancer Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. OncoTherapy Science Peptide Cancer Vaccine Product Portfolios and Specifications
Table 131. OncoTherapy Science Peptide Cancer Vaccine Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. OncoTherapy Science Main Business
Table 133. OncoTherapy Science Latest Developments
LIST OFFIGURES
Figure 1. Picture of Peptide Cancer Vaccine
Figure 2. Peptide Cancer Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide Cancer Vaccine Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Peptide Cancer Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Peptide Cancer Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Peptide Cancer Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Peptide Cancer Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of ITK-1
Figure 12. Product Picture of GRN-1201
Figure 13. Product Picture ofTPIV200
Figure 14. Product Picture ofTPIV110
Figure 15. Product Picture of UV1
Figure 16. Product Picture of Galinpepimut-S
Figure 17. Product Picture ofTARP 27-35
Figure 18. Product Picture of HER-Vaxx
Figure 19. Product Picture of Vx-001
Figure 20. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2025
Figure 21. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2020-2025)
Figure 22. Peptide Cancer Vaccine Consumed in Breast Cancer
Figure 23. Global Peptide Cancer Vaccine Market: Breast Cancer (2020-2025) & (K Units)
Figure 24. Peptide Cancer Vaccine Consumed in Lung Cancer
Figure 25. Global Peptide Cancer Vaccine Market: Lung Cancer (2020-2025) & (K Units)
Figure 26. Peptide Cancer Vaccine Consumed in Melanoma
Figure 27. Global Peptide Cancer Vaccine Market: Melanoma (2020-2025) & (K Units)
Figure 28. Peptide Cancer Vaccine Consumed in Prostate Cancer
Figure 29. Global Peptide Cancer Vaccine Market: Prostate Cancer (2020-2025) & (K Units)
Figure 30. Peptide Cancer Vaccine Consumed in Others
Figure 31. Global Peptide Cancer Vaccine Market: Others (2020-2025) & (K Units)
Figure 32. Global Peptide Cancer Vaccine Sale Market Share by Application (2024)
Figure 33. Global Peptide Cancer Vaccine Revenue Market Share by Application in 2025
Figure 34. Peptide Cancer Vaccine Sales by Company in 2025 (K Units)
Figure 35. Global Peptide Cancer Vaccine Sales Market Share by Company in 2025
Figure 36. Peptide Cancer Vaccine Revenue by Company in 2025 ($ millions)
Figure 37. Global Peptide Cancer Vaccine Revenue Market Share by Company in 2025
Figure 38. Global Peptide Cancer Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 39. Global Peptide Cancer Vaccine Revenue Market Share by Geographic Region in 2025
Figure 40. Americas Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 41. Americas Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 42. APAC Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 43. APAC Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 44. Europe Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 45. Europe Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 46. Middle East & Africa Peptide Cancer Vaccine Sales 2020-2025 (K Units)
Figure 47. Middle East & Africa Peptide Cancer Vaccine Revenue 2020-2025 ($ millions)
Figure 48. Americas Peptide Cancer Vaccine Sales Market Share by Country in 2025
Figure 49. Americas Peptide Cancer Vaccine Revenue Market Share by Country (2020-2025)
Figure 50. Americas Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 51. Americas Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 52. United States Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 53. Canada Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 54. Mexico Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 55. Brazil Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 56. APAC Peptide Cancer Vaccine Sales Market Share by Region in 2025
Figure 57. APAC Peptide Cancer Vaccine Revenue Market Share by Region (2020-2025)
Figure 58. APAC Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 59. APAC Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 60. China Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Japan Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. South Korea Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Southeast Asia Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 64. India Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 65. Australia Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 66. ChinaTaiwan Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 67. Europe Peptide Cancer Vaccine Sales Market Share by Country in 2025
Figure 68. Europe Peptide Cancer Vaccine Revenue Market Share by Country (2020-2025)
Figure 69. Europe Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 70. Europe Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 71. Germany Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72.France Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 73. UK Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 74. Italy Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 75. Russia Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 76. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Country (2020-2025)
Figure 77. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Pipeline (2020-2025)
Figure 78. Middle East & Africa Peptide Cancer Vaccine Sales Market Share by Application (2020-2025)
Figure 79. Egypt Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 80. South Africa Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 81. Israel Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 82.Turkey Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 83. GCC Countries Peptide Cancer Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Peptide Cancer Vaccine in 2025
Figure 85. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 86. Industry Chain Structure of Peptide Cancer Vaccine
Figure 87. Channels of Distribution
Figure 88. Global Peptide Cancer Vaccine Sales MarketForecast by Region (2026-2031)
Figure 89. Global Peptide Cancer Vaccine Revenue Market ShareForecast by Region (2026-2031)
Figure 90. Global Peptide Cancer Vaccine Sales Market ShareForecast by Pipeline (2026-2031)
Figure 91. Global Peptide Cancer Vaccine Revenue Market ShareForecast by Pipeline (2026-2031)
Figure 92. Global Peptide Cancer Vaccine Sales Market ShareForecast by Application (2026-2031)
Figure 93. Global Peptide Cancer Vaccine Revenue Market ShareForecast by Application (2026-2031)
